Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will include glioblastoma and cancers which have spread to the brain (metastases).
Neoplasms
DRUG: BIBW 2992
Objective Response (OR), OR is defined as complete response and partial response (PR) and was assessed according to the Macdonald criteria for glioblastomas and brain metastases and according to Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST) for solid tumours (excluding glioblastomas)., Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter.|Average Time-matched QT Corrected by the Fridericia Formula (QTcF) Change From Baseline to Day 14, Average time-matched QT corrected by the Fridericia formula (QTcF) change from baseline to day 14 over 1 to 24 hours following administration of afatinib., The day before the first drug dose (baseline) and the day 14. Electrocardiograms (ECG) were performed at time point 0 and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h, 24 h thereafter.
Progression-free Survival (PFS), PFS was defined as the time from the first treatment to the occurrence of tumour progression or death, whichever came first. It was assessed according to the Macdonald criteria for glioblastomas and brain metastases and according to RECIST for solid tumours (excluding glioblastomas) as well as by the investigators assessment. Median time results from unstratified Kaplan-Meier estimates., Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter.|Overall Survival (OS), Overall survival (OS) is defined as time from start of treatment to death., Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter.|Disease Control, Disease control was defined as CR, PR or stable disease (SD) and was assessed according to the Macdonald criteria for glioblastomas and brain metastases and according to RECIST for solid tumours (excluding glioblastomas)., Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter.|Duration of Disease Control (DC), Duration of Disease control (DC). DC was defined as CR, PR or stable disease (SD) and was assessed according to the Macdonald criteria for glioblastomas and brain metastases and according to RECIST for solid tumours (excluding glioblastomas)., Tumour assessments were performed at screening, week 8, week 16, week 24, and every 8 weeks thereafter.|Patients With Notable Findings in QTcF on Day 14, Notable findings are defined as a QTcF\>500 ms or an increase in QTcF of \>60ms., Day 14|Patients With Clinically Relevant Findings in ECG on Day 14, Patients with clinically relevant findings in Electrocardiogram data (ECG) on day 14., Day 14|Time-matched QTcF Changes From Baseline to Day 14 at Each Time-point, Individual QTcF measurements at each time-point. Response was defined as the change from baseline. Analysis adjusted for baseline using a mixed model., Baseline and day 14 (at 1, 2, 3, 4, 5, 6, 7, 10, 24 hours post-dose )|Average Time-matched QT Change From Baseline to Day 14, Average time-matched QT change from baseline to day 14 over 1 to 24 hours following administration of afatinib., The day before the first drug dose (baseline) and the day 14. Electrocardiograms (ECG) were performed at time point 0 and 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 7 h, 10 h, 24 h thereafter.|Patients With Notable Findings in QT on Day 14, Number of Patients with notable findings in QT on day 14. Notable findings are defined as a QT\>500 ms., Day 14|Average Time-matched Heart Rate Change From Baseline to Day 14., Average time-matched heart rate change from baseline to day 14., The day before the first drug dose (baseline) and the day 14.|Highest CTC Grade for Adverse Events, Highest Common Terminology Criteria (CTC) grade for adverse events, First administration of trial medication until 28 days after last administration of trial medication|Area Under Curve 0-24 Hours (AUC0-24) on Day 1, AUC0-24 represents the area under the concentration curve of afatinib in plasma from 0 to 24 hours on Day 1., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 1|Maximum Concentration (Cmax), Cmax represents the maximum measured concentration of afatinib in plasma on Day 1., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 1|Time From Dosing to the Maximum Concentration (Tmax), tmax represents the time from dosing to the maximum concentration of afatinib in plasma on Day 1., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 1|Area Under Curve of Afatinib Over a Uniform Dosing Interval Tau at Steady State (AUCtau,ss), AUCtau,ss represents the area under the concentration curve of afatinib in plasma over a uniform dosing interval tau (24h) at steady state (Day14)., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 14|Maximum Concentration of Afatinib in Plasma at Steady State (Cmax,ss), Cmax,ss represents the maximum measured concentration of afatinib in plasma at steady state (Day 14)., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 14|Time From Dosing to the Maximum Concentration of Afatinib in Plasma at Steady State (Tmax,ss), tmax,ss represents the time from dosing to the maximum concentration of afatinib in plasma at steady state (Day 14)., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 14|Accumulation Ratio of AUC Values (R_A,AUC), R_A,AUC represents the accumulation ratio of AUC values after multiple dose administration over a uniform dosing interval t between days 1 and 14, 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 1 and 14|Accumulation Ratio of AUC Values (R_A,Cmax), R_A,Cmax represents the accumulation ratio of Cmax values after multiple dose administration over a uniform dosing interval t between days 1 and 14, 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 1 and 14|Percentage Peak Trough Fluctuation (PTF), PTF represents the percentage peak trough fluctuation. PTF is defined as difference between maximum and minimum concentration at steady state divided by the average concentration multiplied with 100 to report as percentage., 0.05 hours (h) before dosing and 1h, 2h, 3h, 4h, 5h, 6h,7h, 10h and 24h after dosing on Day 14
A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers. Cancers studied will include glioblastoma and cancers which have spread to the brain (metastases).